We expressed ^V600E^BRAF in the melanocytes of 2-month old mice^[@R6]^ and one month later, protected half of the shaved backs of the mice with a cloth and exposed the other half to low doses of UVR ([Fig 1a](#F1){ref-type="fig"}, [Extended Data Fig. 1a, 1b](#SD3){ref-type="supplementary-material"}). UVR upregulates Trp53^[@R7]^, and within 24h of a single UVR exposure we observed Trp53 staining in \~41% of epidermal keratinocytes and down into the reticular dermis ([Fig. 1b](#F1){ref-type="fig"}; [Extended Data Fig. 1c](#SD3){ref-type="supplementary-material"}, [Table 1](#SD3){ref-type="supplementary-material"}). We also observed abundant sunburn cells (\~17 cells/mm) in the basal layer of the UVR-exposed skin ([Fig. 1c](#F1){ref-type="fig"}; [Extended Data Table 1](#SD3){ref-type="supplementary-material"}). The skin did not blister, but after 24-48 hours it developed mild erythema, and after seven days it was rough to the touch, presented fine desquamation and was thickened due to hyperkeratosis, epidermal hypertrophy and a thickened fibrotic dermis ([Fig. 1d](#F1){ref-type="fig"}).

UVR induces melanocyte proliferation^[@R8]^, and naevogenesis is driven by clonal expansion of melanocytes expressing mutant *BRAF*, the acquisition of which is an early event^[@R3]^. Furthermore, the incidence of acquired human naevi, \~80% of which carry *BRAF* mutations^[@R9]^, is linked to UVR exposure^[@R10]^. We show that UVR induced ^V600E^BRAF-melanocyte proliferation *in vivo* ([Extended Data Fig. 2](#SD3){ref-type="supplementary-material"}) and within 7 days, the UVR-exposed skin presented more abundant and larger naevi ([Fig. 1d](#F1){ref-type="fig"}; [Extended Data Fig. 3a-d](#SD3){ref-type="supplementary-material"}; [Extended Data Table 2](#SD3){ref-type="supplementary-material"}). These UVR-induced changes persisted ([Fig. 1e](#F1){ref-type="fig"}) and the UVR-exposed skin darkened ([Fig. 1f](#F1){ref-type="fig"}). UVR did not induce naevi or skin darkening in non-^V600E^BRAF mice ([Extended Data Fig. 3e, 3f](#SD3){ref-type="supplementary-material"}). Thus, we validate human epidemiological studies by showing that ^V600E^BRAF-expressing melanocytes are susceptible to proliferation and naevogenesis driven by low-dose UVR that mimics mild sunburn.

As reported^[@R6]^, ^V600E^BRAF induced melanoma in \~70% of mice at a median latency of 12.6 months. On average each mouse developed 0.9 tumours on its back ([Fig 2a, 2b](#F2){ref-type="fig"}). When exposed to UVR, all ^V600E^BRAF mice developed melanoma within 7 months at a median latency of 5.3 months and an average of \~3.5 (range 1-6) tumours each, 98% (59/60) of which were within the UVR-exposed area ([Fig 2a-2c](#F2){ref-type="fig"}). UVR did not induce melanoma in non-^V600E^BRAF mice ([Fig. 2a](#F2){ref-type="fig"}). Thus, we concluded that UVR accelerated ^V600E^BRAF-driven melanomagenesis.

The UVR and non-UVR tumours were asymmetrical, predominantly amelanotic and locally destructive ([Fig. 2d](#F2){ref-type="fig"}, [Extended Data Fig. 4a, 4b](#SD3){ref-type="supplementary-material"}). They invaded the deeper subcutis, presented superficial naevi and pigmented cells and \~50% ulcerated the overlying epidermis ([Fig. 2e, 2f](#F2){ref-type="fig"}, [Extended Data Fig. 4b](#SD3){ref-type="supplementary-material"}). The tumour cells were atypical with dendritic/plump spindle morphology, and S100 and Hmb45/MelanA positive ([Fig. 2e, 2f](#F2){ref-type="fig"}, [Extended Data Fig. 4c-e](#SD3){ref-type="supplementary-material"}). They were heterogeneous, highly mitotic (20 mitoses/10 high-power fields; 10 tumours analysed) and Ki-67 positive (26.4%, range 10-50; [Extended Data Fig. 4a, 4f](#SD3){ref-type="supplementary-material"}).

Application of sunscreen (UVA superior, UVB SPF 50) 30 minutes before UVR exposure blocked induction of Trp53 and apoptosis in the epidermal keratinocytes ([Extended Data Fig. 5a-c](#SD3){ref-type="supplementary-material"}, [Extended Data Table 1](#SD3){ref-type="supplementary-material"}). These are largely UVB-driven responses^[@R7]^, but sunscreen also blocked UVA-induced epidermal hypertrophy and dermal thickening ([Extended Data Fig. 5d](#SD3){ref-type="supplementary-material"}). The cloth-protected and sunscreen-protected naevi were indistinguishable and sunscreen prevented UVR-driven skin darkening ([Extended Data Fig. 6a, 6b](#SD3){ref-type="supplementary-material"}). Thus sunscreen protected the epidermis from the immediate effects of UVA and UVB, but nevertheless all of the sunscreen-protected UVR-exposed ^V600E^BRAF-mice developed tumours within 15 months at a median latency of 7.5 months ([Fig. 2a](#F2){ref-type="fig"}), a significant reduction compared to unprotected mice, but a significant increase compared to non-UVR-exposed mice (p=0.03; Fisher Exact Test). Sunscreen protected mice developed \~1.5 tumours on their backs, again significantly fewer than unprotected mice, but significantly more than non-UVR-exposed mice ([Fig. 2b, 2c](#F2){ref-type="fig"}). The sunscreen-protected melanomas presented similar histology to non-UVR and UVR-exposed melanomas ([Fig. 2d-f](#F2){ref-type="fig"}, [Extended Data Fig. 6c](#SD3){ref-type="supplementary-material"}) and were more common on sunscreen-protected (14 tumours) than cloth-protected (8 tumours) skin. Thus, sunscreen only partially prevented acceleration of ^V600E^BRAF-driven melanomagenesis by UVR.

Array comparative genome hybridisation revealed no significant differences in gross chromosomal aberrations or copy number variations between non-UVR and UVR melanomas ([Fig. 3a](#F3){ref-type="fig"}), but the non-UVR melanomas presented significantly more (60% vs. 13.3%) recurrent copy number changes in melanoma oncogenes and tumour suppressors (*MITF, BRAF, CCND1, CDKN2A*; [Fig. 3b](#F3){ref-type="fig"}; [Supplementary Table 1](#SD2){ref-type="supplementary-material"})^[@R11]^. Whole exome sequencing (WES) revealed that UVR-exposed melanomas presented significantly more somatic single nucleotide variants (SNVs; median 6.16 \[range 0.26-40.69\] vs. 0.19 SNVs/Mb \[range 0.02--2.16\]; [Fig. 3c](#F3){ref-type="fig"}; [Supplementary Table 1](#SD2){ref-type="supplementary-material"}) and a significantly higher proportion of C to T transitions (median 16.7% vs. 76.6%) at the 3′ end of pyrimidine dimers than non-UVR tumours ([Fig. 3d, 3e](#F3){ref-type="fig"}). This provides direct evidence of UVR-induced DNA damage^[@R12]^ and notably, although sunscreen significantly reduced the number of SNVs (median 0.25050 SNVs/Mb \[range 0.08233 - 0.64432\]) in UVR-exposed melanomas ([Figure 3c](#F3){ref-type="fig"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"}), the tumours still presented a higher proportion of C to T transitions at the 3′ end of pyrimidine dimers than non-UVR exposed melanomas ([Fig. 3d, 3e](#F3){ref-type="fig"}). Thus, sunscreen reduced overall mutation burden but did not completely block UVR-induced DNA damage.

We observed *Trp53* mutations in 6 of 15 UVR-exposed melanomas, 1 of 11 sunscreen-protected UVR-exposed melanomas, but none of 15 non-UVR-exposed tumours ([Fig 4a](#F4){ref-type="fig"}; [Extended Data Table 3](#SD3){ref-type="supplementary-material"}; [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). We confirmed the *Trp53* mutations ([Fig. 4b](#F4){ref-type="fig"}; [Extended Data Table 3a](#SD3){ref-type="supplementary-material"}) and note that there were no significant differences in the number of SNVs in the UVR-exposed *Trp53*-mutant and *Trp53*-wild-type tumours ([Extended Data Fig. 7a](#SD3){ref-type="supplementary-material"}) suggesting that mutant *Trp53* did not contribute to overall mutation burden. The mutations involved codons H39, S124, R245, R270, C272 and 6/7 were C to T transitions at the 3′ end of pyrimidine dimers ([Extended Data Table 3a](#SD3){ref-type="supplementary-material"}) supporting a direct role for UVR in induction of *Trp53* mutations in melanoma. S124, R245, R270 and C272 are in the Trp53 DNA-binding domain and the corresponding residues (S127, R248, R273, C275) are mutated in human TP53 in melanoma ([Extended Data Table 3a](#SD3){ref-type="supplementary-material"}), producing deleterious effects that severely impair promoter-specific TP53-transcriptional activity ([Extended Data Table 3b](#SD3){ref-type="supplementary-material"})^[@R13]^. R273 and R248 are human cancer mutation hotspots and produce proteins with dominant-negative and other gain-of-function activities^[@R14]-[@R16]^. N-terminal TP53 mutations are rare and H39 is not conserved, but the equivalent residue (Q38) is mutated in human cancer ([Extended Data Table 3a](#SD3){ref-type="supplementary-material"}). Notably, all of the mutant proteins accumulated in our mouse melanomas ([Fig. 4c](#F4){ref-type="fig"}; [Extended Data Table 3a](#SD3){ref-type="supplementary-material"}), suggesting common functional consequences.

Two conditional-inducible mouse alleles for DNA-binding domain Trp53 mutants are available, *Trp53^LSL-R172H^* and *Trp53^LSL-R270H^*. These mutant proteins are functionally similar; they possess dominant-negative and gain-of-function activities, and they accumulate in tumours^[@R16]^. The *Trp53^LSL-R172H^* mice were readily available, so we generated heterozygous mice that expressed one copy of ^R172H^Trp53 in their melanocytes (*Trp53^+/LSL-R172H^;Tyr::CreERT2^+/^*). These mice did not develop melanoma, but when crossed to the ^V600E^BRAF mice (*Trp53^+/LSL-R172H^::Braf^+/LSL-V600E^*;*Tyr::CreERT2^+/o^*), all of the mice developed on average 6 tumours (range 2-10) on their backs within 3.5 months ([Fig. 4d, 4e, 4f](#F4){ref-type="fig"}). The tumours presented the histopathological features of other ^V600E^BRAF-driven melanomas ([Fig 4g, 4h](#F4){ref-type="fig"}; [Extended Data Fig. 7b](#SD3){ref-type="supplementary-material"}). Thus, as with deletion of one copy of the tumour suppressor *Pten* ([Extended Data Fig. 7c](#SD3){ref-type="supplementary-material"})^[@R17]^, we show that mutant *Trp53* accelerated BRAF-driven melanomagenesis (p\<0.0001; Fisher Exact Test).

Finally, analysis of WES data from the Broad Institute^[@R18]^, The Cancer Genome Atlas (TCGA, <https://tcga-data.nci.nih.gov/tcga/>) and Yale^[@R19]^ revealed that *TP53* mutations coincided with a higher proportion of C\>T transitions and a UVR signature in primary and metastatic humans cutaneous melanomas ([Fig. 4i](#F4){ref-type="fig"}; [Extended Data Fig. 7d](#SD3){ref-type="supplementary-material"}; [Extended Data Table 3c](#SD3){ref-type="supplementary-material"}). Thus, in human and mouse melanomas, *Trp53/TP53* mutations were associated with UVR-induced DNA damage, establishing that UVR accelerates melanomagenesis by targeting *TP53/Trp53*.

*TP53* is a recognised UVR target in non-melanoma skin cancers, but is thought not to play a role in melanoma, because frequent p14^ARF^ loss, stabilises HDM2, inactivating TP53^[@R4]^. However, we show that \~40% of mouse and \~20% of human melanomas with evidence of UVR-induced DNA damage carried *Trp53/TP53* mutations^[@R18]^. *Trp53* gene deletions can cooperate with ^V600E^BRAF to induce melanoma in mice and fish^[@R20],[@R21]^, but in UVR-exposed melanomas *TP53*/*Trp53* is mutated rather than lost, generating proteins with gain-of-function and dominant-negative activities^[@R14]-[@R16]^. This suggests a complex role for TP53/Trp53 in melanoma that cannot be accomplished if the protein is lost. Our data establish that *TP53* is a *bona fide* UVR target in melanoma, providing insight into how UVR drives melanoma, albeit through mechanisms that have not yet been elucidated. Mutant TP53 drives tumourigenesis through processes inducing evasion of senescence, activation of autophagy, engagement of DNA-damage responses and oxidative stress pathway reactivation, but individual mutants influence these functions differently. Also, it was recently shown that UVR stimulates melanoma invasion, but the role of TP53 in this remains unknown^[@R22]^. Studies are required to elucidate the role of TP53 in melanoma and to identify other UVR targets in *TP53/Trp53* mutant and *TP53/Trp53* wild-type tumours. Intriguingly, recurrent UVR-signature mutations occur in *RAC1, STK19* and *PPP6C* in melanoma, but their roles in melanomagenesis are currently unknown^[@R18],[@R19]^. It is also unclear what induces ^V600E^BRAF because it is not a UVR-signature mutation. Nevertheless, our data show that ^V600E^BRAF-expressing melanocytes are susceptible to UVR-driven naevogenesis and melanomagenesis.

In previous UVR melanoma models, embryonic mice constitutively expressed oncogenes, generally with loss of tumour suppressor genes, and the mice received a single burning dose of UVR 1-3 days after birth^[@R23],[@R24]^. In this model melanoma is driven by inflammation mediated by IFN secreted by neonatal macrophages, and it does not accelerate ^V600E^BRAF-driven melanoma^[@R25]^. We expressed ^V600E^BRAF at physiological levels in adolescent mice without manipulation of tumour suppressor genes and exposed the mice to repeated low doses of UVR. Thus we mimicked both somatic mutation acquisition and mild sunburn in humans, and our tumours were driven by acquired *Trp53* mutations. Thus, we reveal two UVR melanoma pathways, one driven by inflammation in neonates and one driven by UVR-induced mutations in adults.

Finally, it is accepted that sunscreen protects against squamous cell carcinoma^[@R26]^, but controversy surrounds its' ability to protect against melanoma^[@R27]-[@R29]^. The US Environmental Protection Agency states that there is "no evidence that sunscreens protect you from malignant melanoma" (<http://www.epa.gov/sunwise/doc/sunscreen.pdf>), but we establish that sunscreen delayed UVR-driven melanoma in susceptible mice, validating public health campaigns that promote its use for melanoma. However, sunscreen did not safeguard against UVR completely and we advocate combining it with other sun avoidance strategies, particularly in at-risk individuals with BRAF-mutant naevi^[@R1],[@R30]^.

ONLINE-ONLY METHODS {#S5}
===================

Animal procedures {#S6}
-----------------

All procedures involving animals were approved by the Animal Ethics Committees of the Institute of Cancer Research and Cancer Research UK Manchester Institute in accordance with National Home Office regulations under the Animals (Scientific Procedures) Act 1986 and according to the guidelines of the Committee of the National Cancer Research Institute^[@R31]^. Tamoxifen (Sigma-Aldrich T5648) was freshly prepared in 100% ethanol. For genotyping, genomic DNA was prepared from tail biopsies and PCR was performed using the primers previously described^[@R6]^. Groups of \>10 animals per cohort were based on historical precedent to provide statistically significant survival rates in Kaplan-Meier analysis. No randomisation or blinding were required. Animals were culled when tumour burden reached ethical limits, if the animals displayed signs of ill health or distress, or following a maximum of 24 months on study.

^V600E^BRAF expression and UVR treatments {#S7}
-----------------------------------------

^V600E^BRAF was expressed in female C57BL/6 mouse melanocytes by topical application of tamoxifen to the shaved backs of mice at \~2 months of age. A month later mice were anesthetized and the whole backs were shaved. Half of the shaved backs were covered vertically with a UVR proof cloth, to provide an internal control for non UVR-exposed skin. Each animal was treated with 160 mJ/cm2 UVA/UVB or 15 J/cm2 UVA (Waldmann UV181 lamps fitted with UV 6 or UV A-1 tubes) each week for up to 6 months. For the sunscreen protection experiments, mice were treated with Sunsense Milk Sunscreen SPF50 (FDA standard 2,2 mg/cm2,) by topical application 30 min before UVR exposure.

Histology and immunohistochemistry {#S8}
----------------------------------

For immunohistochemistry, samples were processed as described^[@R6]^. Briefly, sections were deparaffinized with xylene and hydrated with a series of graded alcohol washes. Sections were microwaved in citrate buffer (pH 6) for antigen retrieval and rinsed in PBS washes. Sections were blocked in 1% BSA in PBS, incubated with 1:200 dilutions of anti-S100 (Dako), 1:100 dilutions of anti-Ki-67 (Santa Cruz), 1:200 dilutions of mouse anti-HMB45/MelanA (Abcam), 1:100 Tp53 (Abcam) antibodies. Appropriate negative and positive controls for specificity of staining were included and images were captured using Leica DM4000 B LED automated upright microscope system.

Naevi quantification {#S9}
--------------------

For each animal, at least 3 samples of skin were collected. The skin sections were cut perpendicular to the longitudinal axis of the animals to span the exposed and non-exposed areas of the tamoxifen treated back. Two independent observers (observer 1 and 2, AV and MC respectively) performed naevi quantification. For each animal, naevi were quantified in 3 different skin sections, 1.8 mm width each of UVR-exposed and protected skin. Significance was tested with the Wilcoxon Rank Sum Test. The size of the naevi was measured by a single observer recording the largest diameter for each nevus in 10.8 mm skin of UVR-exposed and non-exposed protected skin and significance tested using the U Mann Whitney Test. Four animals were scored.

Tp53 quantification {#S10}
-------------------

We quantified TP53 by scoring nuclear staining in 500 consecutive keratinocytes for each mouse in UVR exposed, protected, and UVR + sunscreen treated skin. Four animals were scored.

Sunburn cell quantification {#S11}
---------------------------

We quantified sunburn cells in 1mm of interfollicular basal keratinocytes for each mouse in UVR-exposed, protected, and UVR + sunscreen-treated skin. Four animals were scored.

Immunofluoresence (IF) {#S12}
----------------------

3 mm sections of formalin fixed paraffin embedded (FFPE) material were used. Slides were dewaxed and antigen retrieval was performed using citrate buffer pH 6 followed by blocking in PBS-Tween 0.1% + 1% BSA for 15 min and overnight incubation with anti ki67 (Santa Cruz sc-7846) and S100 antibody (1:100 in PBS+1%BSA). Antibody detection was performed using AlexaFluor-conjugated secondary antibodies (Invitrogen). Slides were counterstained with DAPI. Samples were analysed and pictures of the mid dermis were taken using a Leica confocal scanning microscope (Leica Microsystems).

Tumour analysis {#S13}
---------------

Mouse genomic DNA was prepared for aCGH and WES as described in [Supplementary Information](#SD1){ref-type="supplementary-material"}. 107 randomly selected SNVs were validated by Sanger sequencing to reveal a true positive rate of 93.5%.

WES and aCGH {#S14}
------------

75 manually dissected sections of 20 μm snap frozen tissue samples with an estimated tumour cell percentage of at least 80% were used for DNA extraction. Normal DNA was isolated from liver or kidney. DNA extraction was performed using a DNeasy blood and tissue kit (Qiagen). Quality assessment was performed by NanoDrop and Qubit. For aCGH, 2 μg of normal and tumour DNA were hybridized to Nimblegen HX3 MM9 whole genome CGH arrays (100718_MM9_WG_CGH). Normalization, window averaging and segmentation were conducted using the standard Nimblegen aCGH analysis pipeline. The BioConductor package aCGH was used to summarise and plot copy number alterations. For WES, 15 tumours from UVR-exposed areas, 15 tumours from animals not exposed to UVR and 11 tumours from animals exposed to UVR and treated with sunscreen were included. Matched normal DNA samples from liver or kidney were obtained. DNA was extracted from frozen materials. Exome capture was performed using the Agilent SureSelect Mouse exome capture kit 3 μg of gDNA according to the manufactures instructions. Sequencing was performed on Illumina GAIIx and HiSeq machines to produce 74bp paired end reads and quality control was conducted using FASTQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Reads were aligned to the NCBI m37 reference genome using BWA^[@R32]^ (version 0.5.9-r16; default parameters). Duplicate reads were marked by Picard (<http://picard.sourceforge.net/index.shtml>) and base quality score recalibration and local realignment around indels were performed using GATK^[@R33]^ (version v1.2-24-g6478681). Pileup files of on-target high mapping quality bases (read mapping quality ≥30) were generated using Samtools^[@R34]^ (version 0.1.18) and somatic single nucleotide variants (SNVs) were called using Varscan^[@R35]^ (version v2.2.8) methods somatic (parameters -min-var-freq 0.08, -p-value 0.05, -min-avg-qual 20) and processSomatic at positions with coverage ≥10 in the normal and tumour. Likely false positives were removed using predetermined filters^[@R35]^. The somatic mutational status of *Trp53* in all tumour samples was also verified using Somaticsniper^[@R36]^. No mutations in *Trp53* in the NON-UVR melanoma samples were identified by either method. Somatic variants were annotated by the Ensembl Variant Effect Predictor^[@R37]^ using Ensembl version 67 and variants present in dbSNP were excluded.

For Sanger sequencing validation, gDNA was amplified by PCR to confirm selected mutations. The products were directly sequenced using dye-terminator chemistry as previously described^[@R38]^. Sequences were visualized using Sequencher software. Primer sequences are available upon request. 107 randomly selected SNVs were validated by Sanger sequencing, to reveal a true positive rate of 93.5%.
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![UV accelerates ^V600E^BRAF-driven naevogenesis\
**a.** Experimental design.. **b.** Trp53 staining (arrows) in protected and UVR-exposed epidermis 24 hours (24h) after UVR. Bar: 50μm. 5 animals examined. **c.** Hematoxylin and eosin stained section (H&E) of protected and UVR-exposed epidermis 24h after UVR. Arrows: sunburn cells (apoptotic keratinocytes). Bar: 50μm. **d.** H&E of protected and UVR-exposed epidermis 7 days (7d) after UVR. Arrows: dermal naevi; double-headed arrows: epidermal/dermal thickness. Bar: 500μm. **e.** H&E of protected and UVR-exposed epidermis 7 months (7m) after UVR. Arrows: dermal naevi; double-headed arrows: epidermal/dermal thickness. Bar: 500μm. **f.** Protected and UVR-exposed skin 9 weeks after UVR treatments.](emss-57911-f0001){#F1}

![UVR accelerates BRAF^V600^-driven melanomagenesis\
**a.** Kaplan-Meier showing melanoma-free survival in tamoxifen-treated UVR-exposed CreERT2 mice (CreERT2+UVR; n=14); ^V600E^BRAF mice (^V600E^BRAF/non UVR; n=55); UVR-exposed ^V600E^BRAF mice (^V600E^BRAF+UVR; n=19) and UVR-exposed sunscreen-protected ^V600E^BRAF mice (^V600E^BRAF+UVR+SS; n=22). ^V600E^BRAF/non-UVR vs.^V600E^BRAF+UVR, p \<0.0001;^V600E^BRAF+UVR vs. ^V600E^BRAF+UVR+SS, p \<0.0001; ^V600E^BRAF/non-UVR vs. ^V600E^BRAF+UVR+SS, p= 0.0003; Log-rank Test. All tests are 2-sided. **b.** Median tumour numbers in ^V600E^BRAF/non-UVR (non-UVR), ^V600E^BRAF+UVR (UVR) and ^V600E^BRAF+UVR+SS (UVR+SS) mice. The error bars show mean ± SD. \*\*\* p-\<0.0001; \*\* p-\<0.008 Wilcoxon Signed-Rank Test (WSRT). **c.** Photograph of UVR mouse 5.3 months after UVR and UVR+SS mouse 6.5 months after UVR. Yellow arrows: UVR tumours; white arrow: protected tumours. **d.** H&E from non-UVR, UVR and UVR+SS mice. Bar: 0.5mm. **e.** Dashed-boxes from Fig 2d. Black arrows: dermal naevi. Bar: 250μm. **f.** Solid-boxes from Fig 2d; scale bar 50μm. Inset: black arrows: mitotic cells. Bar: 10μm.](emss-57911-f0002){#F2}

![Genome analysis of UVR-driven melanomas\
**a.** Somatic copy number alterations by aCGH in non-UVR and UVR tumours. **b.** Melanoma oncogene and tumour suppressor gene gains (green) and losses (red) by aCGH in non-UVR and UVR tumours. p=0.0171; WRST. **c.** Somatic SNVs/Mb in non-UVR (green), UVR (violet) and UVR+SS (orange) tumours; \*\*\*\*: p=1.79e-06; \*\*\*: p=1.165e-05; ns: not significant p=0.6461; WRST. **d.** Proportion of C\>T (G\>A) transitions at 3′ end of pyrimidine dimers in non-UVR, UVR and UVR+SS tumours. The error bars show the lowest data still within 1.5 IQR of the lowest quartile and highest data within 1.5 IQR of the upper quartile. \*\*\* p\<0.0001, \*\* p=0.007698, \* p= 0.02558; WRST. **e.** Proportion of each nucleotide (A: green, C: blue, G: black, T: red) ±1bp of all C to T (G to A) transitions in non-UVR, UVR and UVR+SS tumours.](emss-57911-f0003){#F3}

![Mutant *Trp53* accelerates ^V600E^BRAF-driven melanomagenesis\
**a.** *Trp53* mutations (wt: wild-type, white; mut: mutant, magenta) in non-UVR, UVR and UVR+SS tumours; \*\* p=0.017; Fisher Exact Test. **b.** Sanger sequencing confirming C\>T, p.H39Y *Trp53* mutation in UVR tumour 2. **c.** Trp53 immunostaining in non-UVR Tumour 1 (*Trp53* wt), UVR Tumour 2 (*Trp53* mut), UVR Tumour 3 (*Trp53* wt), and UVR +SS Tumour 1 (*Trp53* wt). Bar 50μm. **d**. Kaplan-Meier showing melanoma free survival in tamoxifen-treated CreERT2 and CreERT2/^R172H^Trp53 (control; n=42), ^V600E^BRAF/non-UVR (n=35), ^V600E^BRAF/^R172H^Trp53 (n=23) and ^V600E^BRAF+UVR (n=19) mice. ^V600E^BRAF/non-UVR vs. V600E BRAF/^R172H^Trp53, p\<0.0001; ^V600E^BRAF+UVR vs. ^V600E^BRAF/^R172H^Trp53, p\<0.0001; Log-rank Test. **e.** Median tumour numbers in tamoxifen-treated CreERT2/^R172H^Trp53 mice (^R172H^Trp53), ^V600E^BRAF/non-UVR (^V600E^BRAF) and ^V600E^BRAF/^R172H^Trp53 mice. The error bars show mean ± SD. \*\*\*p\<0.0001, WRST. **f.** ^V600E^BRAF/^R172H^Trp53 mouse with multiple tumours (white arrows). **g.** H&E from a ^V600E^BRAF/^R172H^Trp53 tumour. Bar 0.5mm. **h.** Boxed area from Fig. 4g. Bar: 250μm. Inset black arrows: mitotic cells. Bar: 5μm. **i.** Proportion of C\>T (G\>A) transitions in TP53 wild-type (wt) or mutant (mut) human melanomas from the Broad Institute^[@R18]^ (**\*\*\***p=0.002, WRST) and TCGA (<https://tcga-data.nci.nih.gov/tcga/>; \*\*\*\*p=1.79E-05) datasets. The error bars show the lowest data still within 1.5 IQR of the lowest quartile and highest data within 1.5 IQR of the upper quartile.](emss-57911-f0004){#F4}
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